Tests telisotuzumab adizutecan against standard care in colorectal cancer with circulating tumor DNA
Tests telisotuzumab adizutecan alone versus standard care in adults with colorectal cancer.
Key facts
- Who runs it
- AbbVie
- Where
- Seoul, South KoreaSee the 3 sitesAlso in 7 other countries, 45 sites
- Trial code
- Registry title
- A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 140 people, planned
- Started
- 2 Sept 2025
- Expected to end
- Nov 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Telisotuzumab Adizutecan
- Standard of Care
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colon or rectal cancer. The scans show no cancer, but a blood test for tumor DNA (ctDNA) is positive after earlier treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Adenocarcinoma of the colon or rectum, with no cancer seen on CT scans of the chest, abdomen and pelvis within 6 weeks before the first dose
- Earlier treatment
- Must have had at least 3 months of platinum-based doublet chemotherapy after or before surgery. Must not have had topoisomerase inhibitors as part of adjuvant therapy.
- Biomarker or test result
- Circulating tumor DNA (ctDNA) positive within 1 year after adjuvant therapy or tumor surgery. Treatment starts within 6 weeks after the positive result.
Main reasons for not taking part
- No surgical tumor tissue sample available
- History of interstitial lung disease or pneumonitis that needed steroid treatment
- Signs of active interstitial lung disease or pneumonitis on the screening chest CT scan
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Has histologically or cytologically confirmed adenocarcinoma of the colon or rectum
- Surgical tumor material should be available for Signatera ctDNA personalized panel design
- Must have received at least 3 months of platinum-based doublet adjuvant and/or neoadjuvant chemotherapy but may not have been treated with topoisomerase inhibitors as part of adjuvant therapy
- Has no radiographic evidence of disease (NED) confirmed by chest, abdominal, and pelvic computed tomography (CT) scans within 6 weeks prior to Cycle 1 Day 1 (C1D1) dosing
- Circulating tumor deoxyribonucleic acid (ctDNA) positive within 1 year either after the end of adjuvant therapy or after tumor resection in subjects who are receiving neoadjuvant therapy and begin treatment within 6 weeks after ctDNA positivity is confirmed (reported)
- For participants with rectal cancer a total of at least 3 months of perioperative and/or adjuvant platinum-based doublet must have been administered. Please note that short course radiation or long-course chemoradiation does not count towards this 3-month minimum of platinum-doublet perioperative and/or adjuvant therapy
Who cannot take part
- No availability of surgical tissue sample
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan
Where in South Korea
Also in 7 other countries, 45 sites
- Asan Medical CenterSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
About the trial
What the trial wants to find out
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone.
Read full original descriptionShow less
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide.
In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutecan alone. In arm 2 Participants will receive SOC alone. The study will run for a duration of approximately 51 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
The 2 groups in the trial
- Telisotuzumab Adizutecan MonotherapyTreatment being tested
Participants will receive telisotuzumab adizutecan dose A as a monotherapy, during the approximately 51 month study duration.
Treatment: Telisotuzumab Adizutecan
- Standard of Care (SOC)Existing treatment, for comparison
Participants will receive SOC, during the approximately 51 month study duration.
Treatment: Standard of Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects With Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)
- Plain-language title
- Tests telisotuzumab adizutecan against standard care in colorectal cancer with circulating tumor DNAGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 October 2026